Table 2 Clinical characteristics of CLI validation cohort
Validation cohort | Clinical groups [Total N = 177 at onset; N = 61 at recovery] | ||||
|---|---|---|---|---|---|
UM | CM | SMA | DC | CC | |
Onset N (%) | 38 (16.3%) | 35 (24.5%) | 30 (16.3%) | 39 (11%) | 35 (27.3%) |
Recovery N (%) | 18 (36%) | 25 (32%) | 18 (32%) | N/A | N/A |
Age (months) Median (IQR) | 45 (6–145) | 49 (15–165) | 37 (6–150) | 55 (5–150) | 50 (10–100) |
Sex: F/M | 24/14 | 20/15 | 14/16 | 19/20 | 20/15 |
PCV (%) At onset Median (IQR) | 32 (27–35) | 25 (23–30) | 13 (11–15) | 14 (8–23) | 34 (32–35) |
PCV (%) At recovery Median (IQR) | 35 (29–40) | 34 (27–40) | 34 (27–37) | 35 (28–) | 35 (27–40) |
Parasite density At onseta Median (IQR) | 27,429 (1901–54,680) | 5590 (1314–81,923) | 32,131 (2487–103,822) | N/A | N/A |